ACD - a Bio-Techne Brand is a leader in the emerging field of molecular pathology, developing cell- and tissue-based assays and diagnostic tests for personalized medicine.
ACD’s products and services to academia, pharmaceutical and biotechnology companies are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
ACD’s products and services to academia, pharmaceutical and biotechnology companies are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
Location: United States, California, Newark
Employees: 51-200
Phone: +1 510-576-8800
Total raised: $34M
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.06.2015 | Series C | $22M | - |
| 01.11.2012 | Series B | $12M | - |
Mentions in press and media 8
| Date | Title | Description |
| 06.09.2024 | Spatial Visualization of Capsid-Dependent Viral Tropism using RNAscope™ ISH Technology, Upcoming Webinar Hosted by Xtalks | www.acdbio.com/science/applications/research-areas/gene-therapy In this free webinar, explore the cellular tropism of the various adeno-associated virus (AAV) serotypes in a spatial context. Attendees will discover how to detect AAV vector ... |
| 18.06.2015 | Precision medicine: RNA-based diagnostics startup raises $22M Series C | Among others, it’s interested in using its RNA clinical diagnostics in the cancer, neuroscience, infectious disease and stem cell signaling spaces. For research, it’s exploring non-coding RNA, single-cell analysis and gene fusions. The roun... |
| 18.06.2015 | Advanced Cell Diagnostics Raises $22M in Series C Equity Financing | Advanced Cell Diagnostics, Inc. (ACD), a Hayward, California-based leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, raised $22m in Series C equity financing. The round was led by grow... |
| 01.11.2012 | Advanced Cell Diagnostics Raises $12M in Series B Financing | Advanced Cell Diagnostics Inc. (ACD), a Hayward, CA-based life science research and clinical diagnostics company, has raised $12m in Series B financing. Backers include New Leaf Venture Partners and Morningside Ventures. The company intends... |
| 01.11.2012 | Advanced Cell Diagnostics Inks $12M Series B | HAYWARD, CA, World leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, announced today that it has completed its $12 million Series B equity financing. >> Click here for more fu... |
| 07.12.2009 | Advanced Cell Gets $2.8M | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Worcester, MA-based Advanced Cell Technology, the developer of human embryonic stem cell technology, has raised $2.77 million in financing from debt and options, according to ... |
| 02.09.2009 | Advanced Cell Diagnostics raises other $5.4m in its Series A equity financing | Advanced Cell Diagnostics has completed the second closing of its Series A equity financing from Morningside Ventures, bringing the total capital raised in this round to $5.4m. The funds will allor the Hayward, Ca.-based company to further ... |
| - | Precision medicine: RNA-based diagnostics startup raises $22M Series C | Bay Area startup Advanced Cell Diagnostics just closed out a $22 million Series C financing – with plans to use its RNA-based testing platform to enter the precision medicine market. The funding will help the startup advance in both clinica... |